BIOLOGICAL MODIFIERS

寻求对第二届国际大会的部分支持 生物反应调节剂(BRM)，由 美洲化疗学会(IASC)。国会将 将于1993年1月29日至31日在旧金山海港岛酒店喜来登酒店举行 加利福尼亚州迭戈。国际会计准则理事会的宗旨和目标是：1)提供 各国之间直接交流科学信息的机会 美洲的同事；2)鼓励、鼓励和促进 获取和传播化疗领域的知识 和其他领域；3)加入并提供与国际 化疗学会及与其他科学组织的合作 在实现这些目标方面。本届大会的目标将是： 1)向该领域的科学家介绍各种领域的最新进展 BRM的概念，特别是在许多疾病状态的治疗中， 通过全面的全体讲座、座谈会和研讨会 由该领域公认的权威机构提供。特别关注的将是 潜在的癌症突破性疗法和广泛的 传染性疾病，包括艾滋病。信息将包括预付款 在基础科学和临床信息方面，后者具有 改善病人护理的最终目标。2)为…提供论坛 通过以下途径与BRMS交流最新科学研究成果 提供口头和海报演示文稿，这些演示文稿选自 这一领域的科学家。3)提供一种非正式沟通的方式 该领域的科学家代表多个国家。这些 科学家将包括参与临床实践和 调查性研究，来自学术界、制药行业的研究人员 工业和生物技术组织以及政府和监管机构 官员们。

Partial support is sought for the 2nd International Congress on Biological Response Modifiers (BRM), which is being organized by the Inter-American Society for Chemotherapy, Inc. (IASC). The Congress will be held January 29-31, 1993 at the Sheraton at Harbor Island Hotel in San Diego, California. The IASC aims and objectives are: 1) To provide opportunities for the direct exchange of scientific information amongst colleagues in the Americas; 2) to stimulate, encourage and facilitate the acquisition and dissemination of knowledge in the field of chemotherapy and other areas; 3) to affiliate and provide input with the International Society of Chemotherapy and cooperate with other scientific organizations in fulfilling these objectives. The objectives of this Congress will be: 1) To update scientists in the field with the latest advances in various concepts of BRMs, particularly in the treatment of many disease states, through comprehensive plenary lectures, symposia and workshops presented by recognized authorities in the field. Especially focused upon will be potential breakthrough therapies for cancer and a wide range of infectious conditions, including AIDS. Information will include advances in basic science as well as clinical information, the latter with an ultimate goal of improved patient care. 2) To provide a forum for exchange of recent scientific findings of research with BRMs through proffered oral and poster presentations selected from those submitted by scientists in the field. 3) To provide a means of informal communication of scientists in the field representing a number of countries. These scientist will include physicians involved in both clinical practice and investigative research, researchers from academia, the pharmaceutical industry and biotechnology organizations, and governmental and regulatory officials.